الصفحة الرئيسية>>Signaling Pathways>> Metabolism>> PDE>>DNMDP

DNMDP

رقم الكتالوجGC62234

DNMDP ، وهو مثبط فسفودايستراز 3A (PDE3A) ، هو عامل فعال وسام للخلايا السرطانيةيعزز ربط DNMDP بـ PDE3A التفاعل بين PDE3A و Schlafen 12 (SLFN12)يظهر DNMDP سمية خلوية انتقائية واضحة للخلايا

Products are for research use only. Not for human use. We do not sell to patients.

DNMDP التركيب الكيميائي

Cas No.: 328104-79-6

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
149٫00
متوفر
5 mg
135٫00
متوفر
10 mg
225٫00
متوفر
25 mg
495٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity[1].

DNMDP (0-1000 μM; 48 hours) shows clear cell-selective cytotoxicity[1]. HeLa cells undergo apoptosis upon DNMDP treatment, indicates by caspase activity detected by a caspase-sensitive luciferase assay and by poly ADP ribose polymerase (PARP) cleavage. At a concentration of 100 nM, DNMDP specifically inhibits both PDE3A and PDE3B, weakly inhibits PDE10, and had little or no detectable effect on other phosphodiesterases[1].

[1]. de Waal L, et al. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016 Feb;12(2):102-8.

مراجعات

Review for DNMDP

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DNMDP

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.